Table 1 Baseline patient characteristics

Baseline characteristics	First ablation			Re-do ablation		
	RF group (N = 346)	EIVOM/RF group (N = 133)	p value	RF group (N = 38)	EIVOM/RF group (N = 43)	p value
Male, n (%)	252 (73)	104 (78)	0.23	29 (76)	34 (79)	0.09
Age, mean (SD), y	68 (8.9)	67 (8.0)	0.39	64 (11)	66 (11)	0.41
Long-standing persistent AF, n (%)	184 (53)	57 (43)	0.04	19 (50)	13 (30)	0.07
Structural heart disease, n (%)	75 (22)	22 (17)	0.21	10 (26)	7 (16)	0.27
ICM	23	3		4	5	
DCM	22	8		2	1	
HCM	10	6		1	1	
VD	18	5		3	0	
CHD	2	0		0	0	
LAD, mean (SD), mm	49 (6.1)	49 (5.0)	0.31	47 (5.7)	46 (6.4)	0.43
EF, %	60 (11)	59 (10)	0.17	60 (10)	63 (9.3)	0.20
BNP, median (IQR) pg/ml	125 (79−225)	112 (71−199)	0.51	80 (35−122)	72 (46−121)	0.48
GFR, ml/min	63 (52−72)	61 (49−69)	0.07	66 (56−76)	61 (48−70)	0.08

AAD, n (%)	24 (7.0)	11 (8.3)	0.61	5 (13)	8 (19)	0.50
HT	225 (65)	88 (66)	0.81	24 (63)	29 (67)	0.69
DM	84 (24)	37 (28)	0.42	10 (26)	12 (28)	0.87
CHADS2 score, mean (SD)	1.2 (0.84)	1.2 (0.86)	0.88	1.2 (0.99)	1.3 (0.88)	0.65
CHA2DS2-VASc score	1.6 (0.85)	1.6 (0.95)	0.99	1.5 (1.1)	1.7 (1.0)	0.50

AAD, anti-arrhythmic drug; AF, atrial fibrillation; BNP, brain natriuretic peptide; CHD, congenital heart disease; DCM, dilated cardiomyopathy; DM, diabetes mellitus; EF, ejection fraction; EIVOM, ethanol infusion in the vein of Marshall; GFR, glomerular filtration rate; HCM, hypertrophic cardiomyopathy; HT, hypertension; ICM, ischemic cardiomyopathy; LAD, left atrial diameter; RF, radiofrequency; SD, standard deviation; VD, valvular disease